Bayer bets on ophthalmology with Perfuse buy

Bayer is buying Perfuse Therapeutics in a deal worth up to $2.45 billion, adding full rights to PER-001, an investigational intravitreal implant now in Phase II development for glaucoma and diabetic retinopathy. The agreement, announced May 6, 2026, includes $300 million upfront plus development, regulatory, and commercial milestones, and still needs antitrust clearance and Perfuse stockholder approval. Bayer said the acquisition strengthens its ophthalmology pipeline, while Perfuse’s lead program is positioned as a potential disease-modifying therapy targeting ischemia through endothelin receptor blockade rather than the standard pressure-lowering or anti-VEGF approaches. (bayer.com)

Why it matters: For veterinary professionals, this is another sign that large human-health companies are still willing to pay heavily for ophthalmology assets that promise functional vision gains, not just disease control. PER-001 is being developed for human glaucoma and diabetic retinopathy, but its mechanism, improving ocular blood flow and addressing ischemia, reflects a broader industry push toward neuroprotection and disease modification in eye disease. That’s relevant to clinicians watching translational trends in retinal and optic nerve care, especially as sustained-release delivery platforms and vascular-targeted therapies continue to shape expectations across ophthalmology. (bayer.com)

What to watch: The next key question is whether Bayer restarts or reshapes Perfuse’s planned late-stage development, because as of May 8, 2026, PER-001 remains listed in Phase II and no Phase III trial appears on ClinicalTrials.gov. (bayer.com)